The recent buzz around CRISPR-Cas9, a genome editing tool, has revolved around its potential for treating various genetic diseases, including cancer. Jack Hopwood, Intellectual Property Consultant and Bertrand Sautier, Strategic Account Manager at Clarivate Analytics talk about how research activity around CRISPR is being measured by tracking R&D strategies and patents. You will also hear about the importance of protecting intellectual property to help accelerate the pace of innovation and minimize the risk of running into costly disputes.

Recently, the U.S. Patent and Trademark Office's released a dataset that contained over 250,000 records, included patent applications and granted patents; the USPTO was interested in the insights this data could reveal to guide cancer research. Di Cross, Director of Research at Clarivate Analytics, talks about her team’s recent award winning submission to the USPTO’s challenge around data analysis and visualization for the Cancer Moonshot Initiative. Listen as she talks about the Cancer Innovation VU tool and how it is a means for others to explore and interact with data to help accelerate the development of cancer treatment.

Join Chris Willis, Manager of Discovery and Translational Sciences at Clarivate Analytics, as he talks about immuno-oncology, why it is promising for cancer patients and how it continues to evolve. Learn more about the new approved drugs on the market that treat indications of cancer and the way in which Clarivate Analytics supports the research taking place in this exciting new area.

The Cancer Moonshot Initiative is intended to accelerate the pace of cancer research. The field of cancer immunotherapy presents real promise for cancer patients – offering a less toxic treatment protocol that reduces their suffering. Amy Braden, a Solutions Specialist at Clarivate Analytics, provides an analysis of her investigation of the landscape of cancer immunotherapy research. Her report examines the outputs from organizations and institutions that are having the biggest impacts in this area and provides a starting point from which to ask informed questions about immunotherapy research.

Historically, clinicians have fought cancer with tools such as radiation, surgery and chemotherapy, which kill cancerous cells, but also damage healthy cells or nearby tissues. Immuno-oncology presents a whole new treatment paradigm; it tunes the immune system to specifically fight cancer cells with better outcome of survival rates. Richard Harrison, Chief Scientific Officer at Clarivate Analytics, talks about the advent of immuno-oncology therapies, the challenges and competitive environment, and the promise for the future.

Cancer immunotherapy represents a growing research field and is emerging as a powerful weapon for cancer treatment, although it is not yet as widely used as surgery, chemotherapy, and radiation therapy. This series of podcasts aims to disseminate the scientific landscape in immuno-oncology to professionals in the field, with comprehensive insights from industry experts, presented in concise and digestible episodes.